Elutia Inc. ELUT
0.81 USD -0.02 (-2.41%)
Regular-session close
0.81 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
0.8051 Day range 0.8384
0.50 52-week range 1.39
- YTD
- +16.88%
- 1 year
- +22.91%
News
globenewswire.com Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, Md., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a drug delivery company built to stop surgical infections, today announced that it granted…
seekingalpha.com Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript Elutia Inc. (ELUT) Q3 2026 Earnings Call Transcript
benzinga.com Elutia Q3 2026 Earnings Call Transcript Elutia (NASDAQ:ELUT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
globenewswire.com Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch Elutia Reports Q3 2026 Results: As Plastic Surgeons Cite Infection Risk at National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch
globenewswire.com Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 GAITHERSBURG, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its…
defenseworld.net Financial Analysis: Elutia (NASDAQ:ELUT) & QuidelOrtho (NASDAQ:QDEL) QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Elutia (NASDAQ: ELUT - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses…
defenseworld.net Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW) Elutia (NASDAQ: ELUT - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies…
globenewswire.com Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its…
globenewswire.com Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills,…
defenseworld.net Jushi (OTCMKTS:JUSHF) vs. Elutia (NASDAQ:ELUT) Head-To-Head Survey Elutia (NASDAQ: ELUT - Get Free Report) and Jushi (OTCMKTS:JUSHF - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based…
globenewswire.com Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills,…
globenewswire.com Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing…
globenewswire.com Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and…
seekingalpha.com Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
globenewswire.com Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The…
globenewswire.com Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market $10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation…
globenewswire.com Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its…
globenewswire.com Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
globenewswire.com Elutia to Present at Planet MicroCap Showcase 2026 on June 17th GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills,…
globenewswire.com Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity…
seekingalpha.com Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
